Serum visfatin, adiponectin, and tumor necrosis factor alpha (TNF-α) levels in patients with psoriasis and their correlation with disease severity

Acta Dermatovenerologica Croatica

Volumn 24, Issue 1, 2016, Pages 13-19

  Sereflican, Betul ^a   Goksugur, Nadir ^a   Bugdayci, Guler ^a   Polat, Mualla ^a   Parlak, Ali Haydar ^a  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

Author keywords

Adipokines; Adiponectin; Obesity; Psoriasis; TNF alpha; Visfatin

Indexed keywords

ADIPONECTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA; ADIPOQ PROTEIN, HUMAN; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; TUMOR NECROSIS FACTOR;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PSORIASIS; SCORING SYSTEM; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADIPONECTIN; ADULT; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PSORIASIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84964285628     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Nestle FO. Psoriasis. Curr Dir Autoimmun 2008;10: 65-75.
2. Krueger G, Ellis CN. Ellis, Psoriasis--recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005;53:94-100.
3. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008;34:2-11.
4. Fonseca-Alaniz MH, Takada J, Alonso-Vale MIC, Lima FB. Adipose tissue as an endocrine organ: from theory to practice. Pediatr (Rio J) 2007;83:192-203.
5. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-32.
6. Chudek J, Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep 2006;58 Suppl:81-8.
7. Vazquez-Vela ME, Torres N, Tovar AR. White adipose tissue as endocrine organ and its role in obesity. Arch Med Res 2008;39:715-28.
8. Guzik TJ, Mangalat D, Korbut R. Adipocytokines-novel link between inflammation and vascular function? J Physiol Pharmacol 2006;57:505-28.
9. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008;14:741-51.
10. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30.
11. Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007;25:529-34.
12. Kalkan G, Karadağ S. The association between psoriasis and cardiovascular diseases. Eur J Gen Med 2013;10:10-16.
13. Gisondi P, Ferrazi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenereol Croat 2010;18:297-304.
14. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999;38:241-251.
15. Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 2003;21:392-97.
16. Mussi A, Bonifati C, Carducci M, D’Agosto G, Pimpinelli F, D’Urso D, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997;11:115-18.
17. Ragab HM, El Maksoud NA, Farid Roaiah MM. Biochemical significance of proinflammatory cytokines in psoriasis vulgaris among Egyptian patients. J Am Sci 2010;6:423-9.
18. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005;2005:273-79.
19. Borska L, Fiala Z, Krejsek J, Andrys C, Vokurkova D, Hamakova K, et al. Selected immunological changes in patients with Goeckerman’s therapy TNFalpha, sE-selectin, sP-selectin, sICAM-1 and IL-8. Physiol Res 2006;55:699-706.
20. Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectintargeted drug development strategies. Trends Pharmacol Sci 2009;30:234-9.
21. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, et al. Plasma adiponektin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008;159:1207-8.
22. Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008;159:1364-67.
23. Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009;55:62-3.
24. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci 2009;55:202-4.
25. Oon HH, Liew CF, Theng CCT, Ho MSL. Adiponectin is associated with disease activity of psoriasis (abstract). J Am Acad Dermatol 2009;60:AB 163. Abstract P 3307.
26. Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008;83:804-16.
27. Koczan D, Guthke R, Thiesen HJ, Ibrahim SM, Kundt G, Krentz H, et al. Gene expression profiling of peripheral blood mononuclear leukocytes from pso-riasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005;15:251-57.
28. Zhou X, Krueger JG, Kao MCJ, Lee E, Du F, Menter A, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003;13:69-78.
29. Bozkurt NM, Yıldırım M, Ceyhan AM, Kara Y, Vural H. Psoriasisli hastalarda serum visfatin duzeylerinin araştırılması. Turkderm 2010;44:15-8.
30. Ismail SA, Mohamed SA. Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. Br J Dermatol 2012;167:436-9.
31. Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U. Leptin, adiponectin, visfatin and retinol-binding protein-4 mediators of comorbidities in patients with psoriasis? Exp Dermatol 2012;21:43-7.
32. Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT, et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007;56:1216-20.